Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Gilead Sciences, Inc. announced on 9 May that it will acquire privately held XinThera, Inc. for an undisclosed price, although the biotechnology giant said the transaction will reduce its GAAP and non-GAAP earnings per share by about $0.12 and $0.15, respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?